Takeda has filed for approval in Japan for Actos (pioglitazonehydrochloride; formerly AD-4833), one of the new products expected to drive growth at the firm over the next few years. Takeda is seeking approval to market the drug for the management of patients with non-insulin-dependent (type II) diabetes.
Pioglitazone is a member of the thiazolidinedione class of drugs, currently spearheaded by Sankyo's Noscal (troglitazone). Although their mode of action is still not fully characterized, these drugs are thought to enhance the action of insulin and reduce blood glucose levels. Studies on troglitazone have also shown other effects, including lowering cholesterol, reducing glucose output from the hepatic system and inhibiting glucose synthesis.
Takeda claims that pioglitazone has a more potent hypoglycemic action than troglitazone, and is forecasting approval in Japan within two years. The drug is in Phase II studies in Europe and the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze